- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Evaxion announce 2026 financial calendar | 191 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, November 12, 2025 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, announces its financial calendar... ► Artikel lesen | |
| Mi | Evaxion A/S - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| Sa | Evaxion presents new immune data for AI-designed cancer vaccine | 1 | Investing.com | ||
| EVAXION Aktie jetzt für 0€ handeln | |||||
| 07.11. | Evaxion präsentiert neue Immun-Daten für KI-gestützten Krebsimpfstoff | 1 | Investing.com Deutsch | ||
| 07.11. | Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 | 629 | GlobeNewswire (Europe) | New biomarker and immune data presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual MeetingFollowing the recent presentation of unprecedented two-year clinical efficacy data from the... ► Artikel lesen | |
| 06.11. | Evaxion Biotech ADS GAAP EPS of $0.01 beats by $0.02, revenue of $7.49M beats by $4.99M | 1 | Seeking Alpha | ||
| 06.11. | Evaxion announces business update and third quarter 2025 financial results | 197 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, November 6, 2025 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, provides business update... ► Artikel lesen | |
| 05.11. | What's Next: Evaxion Biotech's Earnings Preview | 1 | Benzinga.com | ||
| 03.11. | Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate | 928 | GlobeNewswire (Europe) | Evaxion introduces EVX-04, a novel vaccine candidate targeting multiple non-conventional ERV tumor antigens, developed with
our AI-Immunology platformEVX-04 is a therapeutic cancer vaccine candidate... ► Artikel lesen | |
| 03.11. | Evaxion A/S - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 31.10. | Evaxion A/S to announce business update and third quarter 2025 financial results on November 6, 2025 | 490 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, October 31, 2025 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, will provide a business update... ► Artikel lesen | |
| 30.10. | Evaxion raises $7.2 million, extending cash runway to second half of 2027 | 269 | GlobeNewswire (Europe) | Gross proceeds from sales of shares amounting to $4.5 million and exercise of warrants providing a further $2.7 millionTotal gross inflow of cash of $14.7 million since the end of the second quarter... ► Artikel lesen | |
| 27.10. | Evaxion names Helen Tayton-Martin as new CEO | 3 | Seeking Alpha | ||
| 27.10. | Evaxion A/S - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 27.10. | Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer | 282 | GlobeNewswire (Europe) | Dr Tayton-Martin brings broad experience of biotech company building, fund-raising, M&A, business development and operations with a strong track record of strategic partnership dealsHer more than 30... ► Artikel lesen | |
| 20.10. | H.C. Wainwright reiterates Buy rating on Evaxion Biotech stock with $16 target | 2 | Investing.com | ||
| 17.10. | ESMO: Evaxion hopes cancer vax data attracts partner after cash crunch forces smaller ph. 2 trial | 3 | FierceBiotech | ||
| 17.10. | Evaxion A/S erhöht Grundkapital durch ADS-Verkäufe und Ausübung von Optionsscheinen | 4 | Investing.com Deutsch | ||
| 17.10. | Evaxion reports 75% response rate in melanoma vaccine trial | 3 | Investing.com | ||
| 17.10. | Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01 | 315 | GlobeNewswire (Europe) | 75% Objective Response Rate as 12 out of 16 advanced melanoma patients had objective clinical responses, with 11 of the 12 responders continuing to respond at 24 months follow-upImmune activation observed... ► Artikel lesen |
1 2 3 4 5 Weiter >>
82 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 89,75 | +0,50 % | BioNTech: Analysten sehen Aktie nach Zahlen im neuen Licht | Die jüngsten Quartalszahlen von BioNTech führten in dieser Woche zu unterschiedlichen Einschätzungen zweier Analystenhäuser. Während UBS das Kursziel leicht anhebt, bleibt Jefferies deutlich positiver.... ► Artikel lesen | |
| EVOTEC | 5,234 | -4,00 % | Nel ASA: Insider kauft Aktien - Evotec, Newron, Rheinmetall, SUSS und ThyssenKrupp im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| QIAGEN | 38,245 | -1,16 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen anlässlich der jüngst präsentierten Quartalszahlen von 50 auf 46 Euro gesenkt, die Einstufung aber auf "Buy" belassen.... ► Artikel lesen | |
| CUREVAC | 4,504 | -1,36 % | HV-Termine: Hauptversammlungen bei bioXXmed, Borussia Dortmund, CureVac, elexxion, Nanofocus, NSI Asset, OTRS | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| AMGEN | 291,80 | +1,04 % | Amgen's Repatha Cuts Cardiovascular Risk By Up To 36% In Phase 3 Trial | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced detailed findings from its Phase 3 VESALIUS-CV clinical trial, revealing that Repatha (evolocumab) significantly reduces major adverse cardiovascular... ► Artikel lesen | |
| NOVAVAX | 6,166 | +1,53 % | NOVAVAX INC steht still - ich rieche gewaltige Bewegung! | ||
| STRYKER | 319,60 | -0,47 % | Canaccord Genuity bestätigt "Buy"-Rating für Stryker nach Investorentag | ||
| BIOGEN | 141,85 | +0,11 % | Biogen Inc.: "LEQEMBI" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom | TOKYO and CAMBRIDGE, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 43,200 | -1,82 % | CRISPR Therapeutics AG: CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310 Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering | -Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in... ► Artikel lesen | |
| CORE ONE LABS | 0,079 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| OCUGEN | 1,065 | +1,09 % | Ocugen Provides Business Update with Third Quarter 2025 Financial Results | Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA)... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 35,000 | -2,70 % | Structure Therapeutics stock holds Outperform rating at BMO ahead of key data | ||
| BEAM THERAPEUTICS | 21,660 | 0,00 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 22,860 | -2,39 % | Arcutis completes enrollment in infant atopic dermatitis study | ||
| AVIDITY BIOSCIENCES | 70,81 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen |
EVAXION A/S ADR gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 5,780 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EVAXION A/S ADR finden Sie auf Wallstreet Online.